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Abstract
Autoimmune diabetes is a chronic autoimmune disease caused by the loss or selective 
destruction of the insulin-producing cells, called pancreatic beta cells. Damage to beta 
cells results in an absence or insufficient production of insulin produced by the body. 
Most cases of autoimmune diabetes have an autoimmune basis, and the immune system 
mistakenly attacks and destroys beta cells. The immune system plays a critical role in 
controlling the development of autoimmune diabetes. Over the past years there have 
been significant progress and an accumulation of scientific evidence for the concept of 
immunotherapy. Immunotherapy for the prevention and treatment of autoimmune dia-
betes has become the main focus of the research community. Three regimens of immuno-
therapy have been investigated: (1) Antigen-specific vaccines: Insulin-related molecules 
have attracted great interest in vaccine development, including the whole recombinant 
human GAD65 (rhGAD65) and the DiaPep277 peptide of HSP60. (2) Systemic immu-
nomodulators: A large number of non–antigen-specific immunomodulators have been 
studied, including monoclonal anti-CD3 antibody, anti–CTLA-4 Ig, TNF-a, IFN-a, 
IL-1R antagonist, regulatory T cells, and dendritic cells. (3) Combination treatments: 
Combination therapies have the ability to enhance efficacy and will become the standard 
of care for autoimmune diabetes. Development of safe and efficient prevention of auto-
immune diabetes is a general public health object in modern countries now. Although 
large numbers of preventive modalities including immunotherapy have been accom-
plished in animal models of autoimmune diabetes, prevention of human autoimmune 
diabetes remains indefinable. Genetic and environmental factors that control the relaps-
ing-remitting course of β-cell destruction, terminating in complete insulin addiction are 
being determined. In the long run, initial prevention of islet autoimmunity will likely be 
the optimal approach to the prevention of autoimmune diabetes. However, environmen-
tal causes of islet autoimmunity need to be well stated. Modest predictive assessment 
of the existing genetic screening tools also means that the number of children requiring 
intervention will stay great, concerning the number of autoimmune diabetes cases pro-
hibited. Nevertheless, combination treatments are more likely to be used for autoimmune 
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diabetes. Primary systemic immunosuppression followed by antigen-specific induction 
of tolerance or islet regeneration is a sound approach.
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1. Introduction
Autoimmune diseases arise due to loss of self-tolerance caused by tissue injury by T cells or 
antibody reactivity to self. There are several causes of autoimmunity that are not fully under-
stood. One of the major causes of autoimmune disease is the activation of self-reactive T and 
B lymphocytes. During T and B cell development, Self-reactive T and B cells should be elimi-
nated by antigen ligation of T cell receptor or B cell receptor. This is known as the mechanism 
of self-tolerance. To maintain the self-tolerance and eliminate the autoreactive cell, T cells and 
B cells undergo a selection process in primary lymphoid organs, the thymus and the bone mar-
row, respectively [1–3]. After somatic mutation of immunoglobulin genes, B cells need to go 
through a second process of selection failing which somatic mutation generates auto reactivity. 
This is called central tolerance. If somehow, central tolerance is not maintained, autoimmunity 
develops. Several autoimmune diseases have been reported until now. Among them, type-1 
diabetes (T1D) is one of the major autoimmune diseases that develop due to the selective auto-
immune destruction of pancreatic beta cells that leads to the insulin insufficiency. There is no 
definite treatment for T1D except life-long insulin therapy. Hence, the generation of insulin 
secreting beta cells and transplanting it to the diabetic patients is an unmet need.
Pluripotent stem cells (PSCs) have the ability to grow indefinitely while maintaining plu-
ripotency. Under the right circumstances, mouse and human stem cells have the potential 
ability to differentiate into disease-relevant cells [4]. The generation of exogenous beta cells 
and its transplantation to replace dead or dysfunctional endogenous beta cell is a potential 
strategy for controlling blood glucose level in diabetic patients. Stem cell-derived beta cells 
have already been generated previously, and it was successfully able to control the blood 
glucose in clinical settings [5]. As autoimmune disease is a continuous process, it is possible to 
develop diabetes again by destructing the pancreatic islets by pathogenic T cells. As a result, 
this will not be a permanent solution for the control of blood glucose level.
It is already well established that regulatory T cells (Tregs), one of the subtype of T cells, are 
able to suppress the hyper activity of other T cells including beta cell-destructing pathogenic 
T cells. But the number of Tregs is relatively limited in mice and human being. The gen-
eration of Tregs in vitro and adoptively transfer them into the diabetic mice will be a great 
strategy for the treatment of diabetes that will reduce the hazards of complicated surgery 
events throughout the life. We already showed that retroviral transduction of genes with T 
cell receptor (TCR) and the transcriptional factor (FoxP3) into PSCs following coculture with 
stromal OP9-DL1/DL4 cells differentiate them into antigen (Ag)-specific Tregs. Our in vitro 
generated Tregs were able to suppress the autoimmune arthritis in a well-established mouse 
model of Ag-induced arthritis (AIA) [6, 7]. In this chapter, we will discuss how Ag-specific 
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Tregs can be generated from PSCs and how they are able to reduce blood glucose level in a 
mouse model of diabetes.
1.1. Epidemiology: incidence and prevalence
T1D is one of the most common chronic diseases in children. Children under 18 years of age 
are mostly affected. In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. 
More than 150,000 children in the United States have T1D; 1.4 million Americans are diag-
nosed with diabetes each year [8]. In children, T1D develops between 5 and 7 years of age and 
at puberty. The incidence for the development of T1D also varies with seasonal changes and 
geography. It seems that autumn and winter are the seasons for higher incidence of diabetes 
as compared to summer. The incidence and prevalence dramatically vary around the world, 
where some countries have 400-fold higher incidence rate compared to the others. The inci-
dence rates of diabetes in China, India, and Venezuela are 0.1 per 100,000 and are far more 
common in Finland. In Finland, the incidence is approaching 50 cases per 100,000 individu-
als per year. Wide variations have been observed between neighboring areas in Europe and 
North America. Estonia is very close to Finland but the incidence of diabetes is less than one-
third as that of Finland. Puerto Rico has an incidence similar to that of the mainland United 
States, whereas neighboring Cuba has an incidence of less than 3 cases per 100,000 [9].
The incidence for the development of T1D is increasing throughout the world. These changes 
are markedly observed in young children from countries with historically high incidence rates. 
Sweden and Norway have reported 3.3% annual increase in T1D rates, and Finland has observed 
a 2.4% annual rise in incidence. Hence, the increase in T1D incidence is not correlated with socio-
economic condition. Most of the autoimmune diseases disproportionally affect women but T1D 
seems to affect men and women equally. Therefore, T1D is different in disease prevalence and 
incidence that suggests that it is a combination of multiple genetic and environmental factors.
1.2. Etiology
T1D is the result of an autoimmune reaction to the proteins of pancreatic islets. There is a 
strong association between T1D and other autoimmune diseases such as Addison’s disease. It 
is also notable that the incidence of autoimmune diseases is increased in family members of 
T1D patients. T1D develops due to the destruction of pancreatic beta cells by autoreactive T 
cells. Other types of diabetes may also develop due to a combination of reduced insulin sensi-
tivity and impaired beta cells function [10]. Diabetes can be inherited or caused by mutations 
in an autosomal dominant gene resulting in the disruption of insulin production. There are 
three types of autoantibodies that are involved in the development of T1D:
1. Islet cell cytoplasmic antibodies: the presence of islet cell cytoplasmic antibodies indicates 
the future development of diabetes. Note that 90% of T1D antibodies are against islet cell 
cytoplasmic protein.
2. Islet cell surface antibodies: there are some other antibodies that are directed toward the 
islet cell surface Ags. Autoantibody against islet cell surface Ag is also detected in almost 
80% of the cases. These antibodies are also positive in type 2 diabetes.
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3. Specific antigenic target of islet cell: 80% newly diagnosed patients represent with auto-
antibody to glutamic acid decarboxylase (GAD). Presence of this antibody is also a strong 
predictor for future development of T1D. Anti-GAD antibody declines over time in T1D. In 
some cases, anti-insulin antibodies are also detected in T1D patients and in relatives [11].
In some cases, some viruses like B4 strain of the coxsackie B virus, German measles, Mumps, 
and Rota viruses are also responsible for the development of diabetes. When a virus invades 
the body, T cells start to produce antibodies against that virus. If some viruses have the same 
Ag as the beta cells, T cells can actually turn against the beta cell and start destroying it.
There is a strong genetic correlation for the development of diabetes though it is not an 
inheritance. It is considered as a complex and multifactorial disease. In the United States, 
individuals who have first-degree relative with T1D have 5% risk for the development of dia-
betes. But in general population this percentage is very low. Monozygotic twins have a high 
risk whereas dizygotic twins have a lower risk. There are a significant percentage of people 
developing diabetes without any family history. Differences in risk are also developed in 
the parents of children. Children who have their mother suffering from T1D have 2% risk of 
developing T1D, but children whose fathers have diabetes have a greater risk [12]. No single 
gene is predicted to develop diabetes, but more than two dozen susceptibility loci have been 
associated with susceptibility to T1D.
2. Pathophysiologic mechanism of T1D
The main factor for the development of autoimmune diabetes is loss of immunologic toler-
ance to β cells. β cells are selectively destructed by autoimmune reaction. Due to loss of immu-
nologic tolerance, autoreactive CD4+ and CD8+ T cells as well as macrophages are infiltrated 
into the pancreatic islet and develop insulitis. During the disease process, several autoantigen 
that are targeted by autoantibodies are detected into the islet. The main autoantigen that may 
be found in the islets are insulin, glutamic acid decarboxylase (GAD65), islet Ag-2 (IA-2), and 
zinc transporter (ZnT8). These autoantibodies are predominantly associated with the devel-
opment of insulitis [13]. Destruction of β cells is not dependent only on autoantigen, it is also 
related to the presence of high-risk human leukocyte antigen (HLA) haplotypes like DR3-DQ2, 
DR4-DQ8, or both [14]. HLA-class II molecules are mainly expressed by Ag-presenting cells 
(APC) like dendritic cells (DCs) and macrophage. In some cases, they are expressed by acti-
vated CD4+ and B cells, even on activated endothelial cells. The presence of high-risk HLA 
molecules on APC may activate CD8+ T cells through CD4+ T lymphocytes. Then CD8+ T cells 
become hyperactivated and initiate the destruction of β cells. This phenomenon is implicated 
in T1D siblings who share the high-risk HLA DR3-DQ2/DR4-DQ8 genotype [15].
Some other pathophysiological mechanisms have been documented. But the two most com-
mon mechanisms for developing T1D are:
1. Gradual β-cell destruction associated with one or multiple islet cell autoantibodies.
2. Development of glucose intolerance and hyperglycemia due to loss of β-cell secretory function.
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The autoimmune process starts with the infiltration of mononuclear cells including autoreac-
tive CD8+ T cells into the pancreas that leads to the destruction of β cell. In the disease pro-
cess, both the cellular and humoral pathways of immunity are involved. However, the role 
of B lymphocytes is not evident in human, only in the laboratory animal such as nonobese 
diabetic (NOD) mice [5]. In NOD mice, B cells infiltrate in the islets of young mice and play a 
role in the initiation of β-cell destruction by the autoimmune response. In some other autoim-
mune diseases like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclero-
sis B-cell-targeted therapy has been used successfully.
There are several features that characterize the T1D as an autoimmune disease. These are 
because of the presence of mononuclear and immunocompetent cells in the infiltrated pan-
creatic islets; association with the class II major histocompatibility complex; islets cell-specific 
auto-antibodies; increase in the number of CD8+ T cells in the pancreas and reduction in the 
number of CD4+ T cell; and response to immunotherapy and other organ-specific autoim-
mune diseases.
The hallmark of T1D is the selective destruction of pancreatic islets. But due to marked het-
erogeneity, it is difficult to follow the destruction of beta cells within the islets. At the onset of 
hyperglycemia islet contain numerous components like infiltrating lymphocytes and mono-
cytes, a mixture of pseudo-atrophic islets, pancreatic polypeptide, and somatostatin [16]. 
Lymphocyte infiltration is prominent when diabetes becomes chronic. Another important 
prerequisite for the development of diabetes is the activation of islet Ag-specific CD4+ T cell 
[17]. Transferring of CD4+ T cells into the nondiabetic mice from diabetic mice also developed 
insulitis and diabetes. It is already reported that CD4+ T cells are able to induce diabetes 
initially and CD8+ T cells participate in damaging the pancreas [18]. Some cytokines are also 
responsible for the development of autoimmune diabetes. High level of IL-2 and IFN-α cor-
relates or enhances the induction of autoimmune diabetes by activating the macrophage in 
experimental models [19]. In the process of infiltration, macrophages are the first cell type 
invading the islets where they produce TNF-alpha and IL-1. TNF-alpha and IL-1 play an 
important role for inducing the structural changes of beta cells and suppression of their insu-
lin releasing capacity.
3. T1D and Tregs
The role of Tregs has been focused in various autoimmune diseases. The vast majority of 
CD4+ and CD8+ T cells are eliminated in the thymus through central tolerance induction 
mechanism. But in some cases, few autoreactive T cells are not eliminated and are released 
to the peripheral circulation. These autoreactive T cells migrate into the pancreas that causes 
the destruction of islets cells and develop diabetes if they are not actively suppressed by 
Tregs. T1D is mainly a T cell-mediated autoimmune disease where pancreatic beta cells are 
destroyed due to the breakdown of tolerance to islets Ag. Initially, autoreactive CD4+ T cell 
subset recognizes self-Ag and produce T helper (Th) 1 cytokine spectrum that initiate the 
autoimmune process. For further processing, CD8+ T cells are necessary [20]. Tregs have 
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the ability to prevent self-reactivity through active suppression [21]. Several studies have 
demonstrated that CD4+ CD25+ Tregs expressing FoxP3 play an indispensable role in the 
maintenance of immune homeostasis by regulating inflammatory response against invading 
pathogens and preventing destruction of autoimmunity [22, 23].
There are a number of autoantigens that are involved in the pathogenesis of T1D. But the true 
primary autoantigen in T1D has not yet been definitively identified. It is very important to 
identify the islet-specific autoantigen for the development of autoantigen-specific tolerance 
induction immunotherapy and for establishing diagnostic and predictive markers of T1D. 
Until now, the most accepted autoimmune features of T1D are the presence of autoreactive 
T cells and autoantibodies in the pancreas. It is also proposed that autoantibody against 
islet autoantigen may appear many years before clinical diagnosis; 90% patients with T1D 
exhibit autoantibodies against islets autoantigen. But it is not clear whether these autoanti-
bodies play a pathogenic role for the development of diabetes. Studies of different animal 
and human models lacking with certain types of cells demonstrated that the lack of Tregs 
or impairment of their function lead to the development of autoimmune disease, including 
diabetes [24, 25].
A number of mouse models suggests that Tregs play an important role to prevent the onset 
of diabetes. But how the Tregs can function in vivo to block the development of diabetes are 
still under investigation. There are some mechanisms that were proposed on the basis of 
mouse models, and its clinical significance is yet to be proved. As autoreactive T cells are 
the main culprits for the development of diabetes, it is essential to control the migration 
or differentiation of autoreactive T cells into the pancreatic lymph node. Tregs present in 
the pancreatic lymph node have the ability to regulate the priming of autoreactive T cells 
by limiting their expansion and differentiation. Tregs also have the ability to interrupt the 
development of autoreactive T cells through limiting the access of autoreactive T cells to DCs 
[26]. By limiting the priming of T cells in the lymph nodes, Treg cell also prevent the T cells 
becoming an effector T cells. Infiltration of autoreactive T cells into the islet is a crucial step 
for the development of inflammation and leading to the destruction of islet. Some chemokine 
receptors like chemokine receptor 3 (CXCR3) secreted by effector T cells are essential for 
infiltrating them into the islets. By exerting their suppressing mechanism, Tregs inhibit the 
expression of CXCR3 and ultimately prevents the infiltration of these cells into the pancreatic 
islets. The most common suppressive cytokine IL-10 and TGF-beta are secreted by induc-
ible Tregs [27, 28]. These two cytokines play an important immunoregulatory role in T1D. 
TGF-beta secreted by Tregs in the islet during the priming phase stimulates the expansion or 
generation of intra-islet FoxP3 expressing Tregs [29]. It is already established that increased 
numbers of Tregs are essential for the suppression of autoreactive T cells that are destruc-
tive to the islets. Migration of autoreactive T cells into the islet worsens the disease condi-
tion. Intracellular adhesion molecule 1 (ICAM1) is one of the potential factors that helps to 
migrate the autoreactive T cells into the islets. ICAM1 is exclusively expressed by autoreac-
tive CD4+ and CD8+ T cells [30, 31]. IL-10 secreted by Tregs downregulates the expression 
of ICAM1 on effector T cells, which prevents their migration to the target organ [32]. IL-10 
also reduces the hyperactivity of T cells by modulating the function of APC and reduces the 
inflammation [33].
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4. Role of Tregs in autoimmunity
Tregs are a subset of T cells that exhibit inhibitory or regulatory effects on effector T cells. 
Previously it was known as suppressor T cells. There is a phenotypical variation of Tregs, 
such as CD4+CD25+FoxP3+ Tregs, CD8+ Tregs, and CD3+ CD4-CD8- Tregs [34, 35]. A dysfunc-
tion, defect, or absence of Tregs has been implicated in the pathogenesis of many autoimmune 
diseases [36] as they are indispensable to maintain the immune homeostasis. However, how 
they control the development of autoimmunity is still under debate. Previous data suggests 
that several numbers of genetic and mechanistic defects may arise leading to defective regula-
tion by Tregs [37]. Though all different types of Tregs work together to maintain the homeo-
stasis, CD4+ FoxP3+ Tregs play the major role because they are the long lasting and produce 
most of the suppressive cytokines. There are several mechanisms by which Tregs exert their 
regulatory effects on effector T cells. These are cell-to-cell contact, secretion of IL-10 and TGF-
beta-like immunosuppressive cytokines, modification or killing of APC, and competition for 
growth factor [38, 39]. CD4+ FoxP3+ Tregs suppresses the immune response, inflammation, 
and tissue destruction by inhibiting the function of classical CD4+ Th cells, antibody produc-
tion of B cells, and CD8+ cytotoxic T lymphocyte granule release. Inducible CD4+ foxP3- type 
1 Tregs or CD4+FoxP3+ Tregs can exhibit their suppressive function through IL-10 secretion. 
Though some other functions of Tregs have been documented but the major function is to 
maintain the immune homeostasis. Deficiency in Treg frequency or function results in imbal-
ance in the immune system. But in some cases there are no apparent defects in Treg frequen-
cies like multiple sclerosis [40]. The result in other autoimmune settings have been mixed, 
but overall in most autoimmune patients, ample number of Tregs appear in the circulation. 
Any discrepancies in the results reflects the nonspecific phenotypic markers available or due 
to contamination with non-Tregs. Until now, almost all studies have been limited to analysis 
of peripheral blood so it is difficult to understand what is happening at the site of inflamma-
tion. A number of studies showed reduced frequencies of Tregs in peripheral blood, but an 
increased number or potency of cells isolated from inflammatory sites [41]. This may be a 
compensatory mechanism in response to ongoing inflammation during the disease process. 
Treg stability is another important issue when assessing the frequency of Tregs. Many auto-
immune diseases are thought to undergo periods of relapse and remission [42]. These varia-
tions are susceptible to the influence of immunosuppressive regimens used in the treatment 
of autoimmune disease. Moreover, during the progression of disease Tregs in local sites can 
change phenotypically.
5. Management of T1D
T1D is a chronic metabolic disorder characterized by deficiency of insulin production by 
pancreatic beta cells. Insulin is essential for maintaining the normal blood glucose level. As 
it is an autoimmune destruction caused by endogenous autoreactive T cells, exogenous insu-
lin supply is required to maintain normoglycemia in many diabetic patients. This is a life-
long treatment that is not convenient. Another option for treatment is replacement of beta 
cell therapy where sufficient amount of beta cells need to be included to control the blood 
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glucose level without repeated insulin injection. However, the beta cell transplantation did 
not achieve a satisfactory result. In 2000, Shapiro and colleagues achieved independence of 
insulin injections in seven T1D patients by transplanting a large number of islet cells com-
bined with the use of glucocorticoid-free immunosuppressive regimen [43]. But the insulin 
independency was not sustained for long. Some patients even had complete graft loss 1 year 
after the final transplantation. The main reason for poor long-term outcome is continuous 
immune destruction of the transplanted islet as autoimmune destruction is a continuous pro-
cess. Beta cell transplantation also has a major obstacle, shortage of donors when compared 
with large population. As cadaver tissue provides a low yield of islet cells, it requires a large 
number of donor cells to generate sufficient insulin-producing beta cells that are capable of 
producing and releasing adequate amount of insulin in response to normal physiological 
signals. Furthermore, chronic immunosuppression is also necessary after allograft transplan-
tation. Patient-specific islet-like cells from adult tissues may compensate both the shortage 
of organ donors and allograft rejection. Several groups were successful to generate func-
tional islet-like clusters from adult progenitor cells, but their success were limited [44, 45]. 
Therefore, it is highly demanding to explore some other option for searching more defined 
sources of beta cells.
Generation of induced PSCs (iPSCs) opens a new era in the treatment of autoimmune dis-
eases. IPSCs have the ability to become all kinds of cells if they are maintained properly [46]. 
As Tregs have the ability to Suppress the hyper activity of autoreactive T cells and they can 
be expanded in vivo after one-time transplant, it is ideal to generate Tregs from iPSCs for the 
treatment of autoimmune diabetes.
6. iPSCs
Due to restricted use of human embryonic stem cells (ESCs) in both research and clinical 
settings, induced pluripotent stem cells (iPSCs) serve as an attractive potential alternative to 
ESCs. Human somatic cells can be reverted back to pluripotent stem cells by expression of 
defined transcription factors. Mouse and human somatic cells have already been converted 
into iPSCs by introducing transcription factors OCT4, and SOX2 in combination with KLF4, 
c-MYC, NANOG, and lin-28 homolog A [47]. iPSCs are similar to ESCs in morphology, 
gene expression, epigenetic status, and in vitro differentiation. C-MYC and KLF4 are known 
oncogenes and their use to generate iPSCs raises concerns about potential tumor formation. 
However, this can be overcome by the use of a histone deacytylase inhibitor, valproic acid, 
which facilitates the reprogramming of primary human fibroblasts with only two factors, 
OCT4 and SOX2. Thus, the reprogramming of cells to pluripotency has become potentially 
safer and practical for therapeutic use [48]. Another challenge was the use of retrovirus or len-
tivirus to deliver transcription factor genes into the somatic cells. This also raised the concern 
about viral integration into the host genome that increases risk of tumorigenicity. To avoid 
this risk, Yamanaka used a novel repeated transfection protocol for the expression of plasmids 
that resulted in iPSCs without evidence of plasmid integration [49]. Other groups also gen-
erated iPSCs from umbilical cord blood by lentiviral overexpression of the reprogramming 
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factor OCT4, SOX2, NANOG, and LIN28 [50]. The reprogramming efficiency was almost the 
same as keratinocytes and fibroblast. However, use of umbilical cord blood also leads to a 
possibility that it may be mutated over the lifetime of an organism. Thus, it is still under 
debate whether iPSCs are truly equivalent to human ESCs or not with respect to pluripotency.
iPSCs have already been used for the generation of Insulin secreting cells. iPSCs were gen-
erated from skin biopsies of a patient with T1D by using three transcription factors OCT4, 
SOX2, and KLF4 [51]. These cells were differentiated into insulin-producing cells. These cells 
were found to be released human C-peptide and exhibited a five-fold increase in the secre-
tion of C-peptide in response to 20 mM glucose, which reveals that functional beta cells can 
eventually be derived from iPSCs.
Generation of functional beta cells for the immunotherapy of T1D is not the only challenge; 
there is a need to overcome the immune response both in terms of autoimmunity and rejec-
tion of allogenic tissue. It is also unknown whether these in vitro generated cells will migrate 
to the target tissue or not. Since beta cells will continuously be destroyed upon development 
of autoimmunity, it is ideal to generate Ag or tissue-specific Tregs from iPSCs for the treat-
ments of autoimmune diabetes.
7. Generation of Ag/tissue-specific Tregs from iPSCs
Tregs have been used for the treatment of autoimmune diseases because it modulates the 
autoimmune response by immune suppression. A number of mouse models demonstrated 
that Tregs are potent inhibitors of polyclonal T cell activation [52]. This Treg-mediated sup-
pression is achieved by cytokine-independent and cell-contact-dependent mechanisms that 
require activation by TCR. When its cognate Ag activates Tregs, they can suppress the con-
ventional T cells within the immediate vicinity regardless of the specificity. In this phenom-
enon, Treg does not need to recognize any specific Ag; they exert their suppressive efforts by 
recognizing the Ag on APC. Thus, any autoimmune affected organ or tissue can be targeted 
without the knowledge of the causative Ag by using Tregs. By utilizing this procedure, the 
maximal therapeutic effect will not be achieved, as it is not Ag-specific. Polyclonal Tregs also 
inhibit a wide range of other immune cells such as B cells, DCs, and monocytes [53–55]. It has 
also been observed that polyclonal Tregs failed to reverse ongoing autoimmunity because 
Tregs require Ag specificity to home/be retained at the appropriate site and exert active sup-
pression. Within a polyclonal population of Tregs, Ag specificity against autoantigen exists in 
a small proportion of cells, which is not sufficient to exert sufficient amount of suppression. 
Therefore, it is crucial to generate a large number of Ag-specific Tregs for adoptive immuno-
therapy to reverse the ongoing autoimmunity.
Since it has been established that Tregs are the most potent to suppress the overactivity of 
hyperactive T cells, our approach was to generate a large number of Ag-specific Tregs from 
iPSCs. It is already published that hematopoietic stem cells (HSCs) and ESCs are able to differ-
entiate into T cells in an in vitro culture system and we have utilized a similar approach to test 
whether iPSCs could follow the same trend [6, 56]. In that study, mouse iPSCs were cocultured 
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with Notch ligand expressing bone marrow stromal cell line (OP9-DL1) as Notch ligand signal-
ing is essential for T lineage differentiation [57]. At different days of cell culture, iPSCs were 
collected and evaluated for morphology, cell surface Ag, and their functional ability. It is found 
that iPSC-derived cells differentiated from stem-like cells to T cell-like cells, expressing T cell 
surface markers. Morphologically, dome-like stem cell colony was transformed to grape-like 
colony, which is a characteristic of lymphoid cells. iPSCs usually express CD117 and Nanog 
surface markers. After differentiation, the cells stopped expressing stem cell-like markers and 
expressed T cell markers such as CD4 and CD8. In vitro differentiated cells were also tested for 
their functional ability and it is found that they secrete IL-2 and IFN-α upon stimulation with 
anti-CD3 and anti-CD28 antibodies.
Since we could differentiate iPSCs into functional T cells, we proceeded to generate Ag-specific 
Tregs. First, we generated a construct called MiDR-TCR-FoxP3 where ovalbumin (OVA)
323–339
 
specific TCR OTII and FoxP3 were cloned into MiDR vector (Figure 1).
MiDR-TCR-FoxP3 vector was retrovirally transduced into mouse iPSCs and cocultured onto 
with OP9-DL1-DL4-I-Ab in the presence of recombinant cytokines of rIL-7 and rFLt3L. TCR 
and FoxP3 gene-transduced iPSCs were checked for differentiation by observing their mor-
phological change. We found that iPSCs differentiated into mesoderm-like cells, and were 
associated with nonadherent grape-like clusters. On day 22 of culture, lymphocyte-like cell 
Spread fully across the plate (Figure 2).
In vitro cocultured cells were analyzed for cell surface markers. We found that the iPSC-
derived cells substantially expressed CD3- and Ag-specific TCR, two T cell markers. The 
Figure 1. Generation of MiDR-TCR-FoxP3 retroviral construct. Schematic representation of the retrovirus construct 
MiDR-TCR-FoxP3 expressing OVA-specific TCR and FoxP3. Ψ, packaging signal; 2A, picornavirus self-cleaving 2A 
sequence; LTR, long terminal repeats.
Figure 2. Morphology of Treg differentiation on days 0, 7, 14, and 22. The TCR/FoxP3 gene-transduced iPSCs were 
cocultured with OP9 stromal cell expressing Notch ligands DL1, DL4, and I-Ab in the presence of rIL-7 and r-Flt3L. 
Morphology was visualized under a microscope.
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CD3+TCRVβ5+ population expressed CD4. Most of the CD3+TCRVβ5+CD4+ cells expressed 
CD25, CD127, and CTLA-4, which are typically expressed at elevated levels in naturally 
occurring Tregs (iTregs) [58]. Subsequently, we also investigated the functional capability of 
iPSC-derived Ag-specific Tregs. After adoptive transfer, CD4+FoxP3+ Tregs were isolated from 
pancreatic lymph nodes and checked for expression of two suppressive cytokines, IL-10 and 
TGFβ. The result showed that significant amount of IL-10 and TGFβ were secreted by Tregs 
that supported that iPSC-derived Tregs are functional.
8. Utilization of iPSC-derived Tregs for the treatments  
of autoimmune diabetes
We developed a mouse model for autoimmune diabetes by crossing B6 mOVA transgenic (Tg) 
mice with OT I TCR Tg mice. In B6 mOVA Tg mice, membrane bound form of OVA expressed 
in the pancreatic islet β cells and the renal proximal tubular cells [59]. Once they are interbred, 
the resulting mice will be B6 mOVA-OT I where T cells from OT1 Tg mice will be directed to 
the pancreas as the pancreas expressed OVA autoantigen. The OT I OVA-specific T cells will 
begin to target and destroy pancreatic islet cells and mice will subsequently develop diabe-
tes. Once pups reached 8 weeks, blood sugar level was measured and it was observed that 
only 30% mice developed diabetes. Subsequently, OT I Tg T cells were further triggered by 
injecting vaccinia virus expressing OVA (VV-OVA) into the mice. After vaccinia immuniza-
tion, 100% mice developed diabetes with more urine discharge. After confirmation of disease 
developed in mice, we injected iPSC-derived Tregs into the mice. One-week post cell transfer, 
we checked the blood glucose level and found that more than 80% of the mice had reduced 
glucose level in their blood. Mice were sacrificed for histological evaluation. Pancreas were 
isolated from treated and untreated mice and it was observed that inflammation was mark-
edly decreased in iPSC-derived Treg-transfer mice compare to untreated mice (Figure 3).
Figure 3. Inflammatory cells are accumulated in diabetic mice: diabetic and Treg-transferred mice were sacrificed and 
pancreases were prepared for HE staining. Untreated mice show large accumulation of inflammatory cell infiltration in 
the pancreas.
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Further analysis was done to check the islet destruction in iPSC-derived Treg-transfer and 
nontransfer mice. Islet sizes were markedly reduced in nontransfer mice, whereas islet sizes 
were normal in iPSC-derived Treg-transfer mice (Figure 4).
We investigated the mechanisms of how iPSCs-derived Tregs controlled blood sugar levels 
and prevented the destruction of islet in autoimmune diabetes mice. Adhesion molecule 
Figure 4. Islet size and numbers were reduced in diabetic mice. Diabetic and Treg-transferred mice were sacrificed and 
their Pancreas were stained with insulin to detect the beta cell. In diabetic mice, islets size and number were reduced 
markedly, whereas islet size and numbers were normal in Treg-transferred mice.
Figure 5. Stem cell-derived OVA-specific Tregs were adoptively transferred into diabetic mice. (A) Tregs induced the 
expression of TGF-β into the destructed islet leading to increase the expression of intra-islet FoxP3 that protected the 
islet from further destruction. (B) Tregs induced the expression of IL-10 into the destructed islet leading to reduce the 
expression of ICAM1 that prevented the migration of CD8+ T cells into the destructed islet and protected the islet from 
further destruction.
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ICAM1 is important for targeting autoreactive CD8+ T cells into the pancreatic islet [32]. 
We determined the expression of ICAM1 into the pancreatic lymph nodes, and found that 
ICAM1 expression was dramatically increased in diabetic mice. Conversely, its expression 
was markedly reduced in iPSC-derived Treg-transfer mice. Previously, we have showed that 
iPSC-derived Tregs were able to secret IL-10 and TGF-β. Therefore, expression of TGF-β by 
iPSC-derived Tregs into the islet increased the intra-islet FoxP3 expression that protected the 
islet from further destruction. Moreover, IL-10 secreted by the Tregs reduced the expression 
of ICAM1, which prevented the migration of autoreactive CD8+ T cell into the damaged islet 
and prevented further destruction of the islet (Figure 5).
9. Conclusion
PSCs have the ability to differentiate into Ag-specific Tregs and they are also found to be 
similar morphologically and functionally to iTregs. However, in autoimmune diabetes, it is 
important to mitigate the disease by increasing the activity of islet cells or preventing their 
destruction from autoreactive T cells. In our study, iPSC-derived Tregs were successful in 
reducing the blood sugar level and restoration of the islet size. By utilizing the knowledge 
from iPSC differentiation, We will be able to generate Ag-specific T cells that are more closely 
associated with the development of autoimmune diabetes. It is already known that heat shock 
proteins (HSPs) are an islet tissue-associated auto-Ag and involved in the islet cell destruction 
of T1D [60]. HSPs can modulate chronic inflammatory diseases and can be a target of immu-
notherapy of T1D. In our preliminary study, we checked the expression of HSPs in our dia-
betes model and found that diabetic mice substantially expressed HSPs. Therefore, it will be 
ideal to generate HSP-specific Tregs from PSCs for the treatment of autoimmune diabetes. For 
this study, HSP-specific TCR needs to be genetically processed and cloned into a viral vector 
to be retrovirally transduced into PSCs and follow the general protocol to allow for in vitro dif-
ferentiation for the development of HSP-specific Tregs. In recent years, not only our efforts in 
utilizing PSC derived T cells for therapeutic purposes, but also other groups have made con-
siderable efforts in understanding the PSC function in hematopoietic development. PSCs also 
could be differentiated into DCs, NK cells, and B cells. Consequently, by using patient-derived 
iPSCs, autoantigen-specific Tregs could be generated to specifically treat diabetic patients.
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